Top

International Urogynecology Journal

Published in:

01-12-2019 | Overactive Bladder | Original Article

Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response

Authors: Mehmet Gokhan Culha, Recep Burak Degirmentepe, Sait Ozbir, Suleyman Sami Cakir, Yukio Homma

Published in: International Urogynecology Journal | Issue 12/2019

Abstract

Introduction and hypothesis

Overactive bladder (OAB) is a syndrome with symptoms such as urinary frequency, urinary urgency and urge incontinence. The aim of this study is to assess the validity and reliability of the Turkish overactive bladder symptom score (OABSS) and to evaluate the results of mirabegron treatment with OABSS.

Methods

The study was carried out with 117 patients who applied to the urology outpatient clinic between June 2018–January 2019. OABSS Turkish validation was developed from the English version. Demographic data of the patients were recorded. The OABSS, overactive bladder questionnaire (OAB-v8) and International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) were filled out by the patients. The patients were asked to fill in these questionnaires after 2 weeks. Patients receiving mirabegon treatment were evaluated with the same questionnaires and bladder diaries after 8 weeks.

Results

A total of 117 OAB patients, including 82 OAB-wet and 35-OAB dry, were included in the study. The mean age of the patients was 46.79 ± 14.26 (18–78) years, and the mean duration of OAB complaint was 32.28 ± 32.21 months. The mean score of the OABSS is 9.9 ± 3.14. The results of the reliability assessment showed that the intraclass correlation coefficient of the total OABSS score was 0.71 (weighted coefficients of individual item points, 0.635–0.831), and the Cronbach α was 0.736. In the validity analysis, the OABSS total score was highly correlated with that belonging to other questionnaire forms (OAB-v8, ICIQ-SF and bladder diary). After the treatment with mirabegron, mean OABSS scores of the patients improved significantly from baseline to the 8th week (p < 0.001).

Conclusion

The Turkish version of the OABSS has been approved as a valid and reliable tool for evaluating OAB. Mirabegron used daily improved the symptoms of OAB in patients.

Available only for authorised users

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78.CrossRefPubMed

Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res: Int J Qual Life Aspects Treat Care Rehab. 2002;11(6):563–74.CrossRef

Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl):S580–90.PubMed

Irwin DE, Milsom I, Kopp Z, Abrams P, Artibani W, Herschorn S. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol. 2009;56(1):14–20. https://doi.org/10.1016/j.eururo.2009.02.026.CrossRefPubMed

Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36. https://doi.org/10.1007/s00345-002-0301-4.CrossRefPubMed

Zumrutbas AE, Bozkurt AI, Tas E, Acar CI, Alkis O, Coban K, et al. Prevalence of lower urinary tract symptoms, overactive bladder and urinary incontinence in western Turkey: results of a population-based survey. Int J Urol : Off J Jap Urol Assoc. 2014;21(10):1027–33. https://doi.org/10.1111/iju.12519.CrossRef

Bradley CS, Rahn DD, Nygaard IE, Barber MD, Nager CW, Kenton KS, et al. The questionnaire for urinary incontinence diagnosis (QUID): validity and responsiveness to change in women undergoing non-surgical therapies for treatment of stress predominant urinary incontinence. Neurourol Urodyn. 2010;29(5):727–34. https://doi.org/10.1002/nau.20818.CrossRefPubMedPubMedCentral

Coyne KS, Tubaro A, Brubaker L, Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology. 2006;68(2 Suppl):9–16. https://doi.org/10.1016/j.urology.2006.05.042.CrossRefPubMed

Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23(4):322–30. https://doi.org/10.1002/nau.20041.CrossRefPubMed

10.

Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003;189(1):98–101.CrossRefPubMed

11.

Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102–9. https://doi.org/10.1016/j.jclinepi.2007.03.012.CrossRefPubMed

12.

Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, et al. Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology. 2006;68(2):318–23. https://doi.org/10.1016/j.urology.2006.02.042.CrossRefPubMed

13.

Homma Y, Fujimura T. Psychometric validation of the English version of the overactive bladder symptom score. Urology. 2014;84(1):46–50. https://doi.org/10.1016/j.urology.2014.03.019.CrossRefPubMed

14.

Tufan Tarcan NM, Ozay Ozgur M, Akbal C. OAB-V8 Aşırı Aktif Mesane Sorgulama Formu Validasyon Çalışması. Üroloji Bülteni. 2012;21:113–6.

15.

Çentinel B, Özkan B, Can G. The validation study of ICIQ-SF Turkish version. 2004 30.

16.

Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Philadelphia: Lawrence Erlbaum Associates; 1988.

17.

Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002;60(5 Suppl 1):7–12 discussion 12.CrossRefPubMed

18.

Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95. https://doi.org/10.1016/j.eururo.2012.10.016.CrossRefPubMed

19.

Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305. https://doi.org/10.1016/j.eururo.2012.10.048.CrossRefPubMed

Title: Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response
Authors: Mehmet Gokhan Culha
Recep Burak Degirmentepe
Sait Ozbir
Suleyman Sami Cakir
Yukio Homma
Publication date: 01-12-2019
Publisher: Springer International Publishing
Keyword: Overactive Bladder
Published in: International Urogynecology Journal / Issue 12/2019
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-019-04054-0

At a glance: The STEP trials

Springer Medicine

Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response

Abstract

Introduction and hypothesis

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2019

Commentary on ‘A longitudinal qualitative evaluation of patient perspectives of adverse events after pelvic reconstruction surgery’

Development and validation of a protocol for documentation of obstetric perineal lacerations

Can wearing high heels influence anal canal pressure and the severity of fecal incontinence?

Interposition of the mesorectal flap as prevention of rectovaginal fistula in patients with endometriosis

Reconstruction of the urethra with an anterior vaginal mucosal flap in female urethral stricture

Prevalence of urinary incontinence in women powerlifters: a pilot study